Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?
Open accessAbstract
Atherosclerosis is a chronic inflammatory disease characterized by lipid and inflammatory cell deposits in the inner layer of large- and medium-sized elastic and muscular arteries. Diabetes mellitus (DM) significantly increases the risk of cardiovascular diseases and the overall and cardiovascular mortality, and it is a pro-atherogenic factor that induces atherosclerosis development and/or accelerates its progression through a multifactorial process. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a new class of drugs, belonging to the armamentarium to fight type 2 DM, that have shown robust reductions in atherosclerotic events and all-cause mortality in all studies. Preclinical studies have shown that GLP-1RAs play a role in the immunomodulation of atherosclerosis, affecting multiple pathways involved in plaque development and progression. In this review, we wanted to explore the translational power of such preclinical studies by analyzing the most recent clinical trials investigating the atheroprotective effect of GLP-1RAs.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
GLP-1RAs have been shown to impact multiple pathways involved in plaque formation, exhibiting atheroprotective effects.
“GLP-1RAs have been shown to impact multiple pathways involved in plaque formation, exhibiting atheroprotective effects.36”
From The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy (2025) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725 · see citing works
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961 · see citing works
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1× · see citing works
“The LEADER (Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes) is the first trial to demonstrate positive outcomes in CVDs in patients with T2DM [34].”
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · see citing works
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · see citing works
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261 · see citing works
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854 · see citing works
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · see citing works
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162 · see citing works
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663 · cited 1× · see citing works
“…showing a significant reduction in MACEs, CV death, stroke, myocardial infarction, death from all causes, heart failure, and kidney disease, emphasizing the important glycometabolic effects and extraglycemic actions that would determine a significant clinical benefit in patients with T2DM [40].”
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601 · see citing works
Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums
Arnold, S. E., Arvanitakis, Z., Macauley-Rambach, S. L., Koenig, A. M., Wang, H.-Y., Ahima, R. S., Craft, S., Gandy, S., Buettner, C., Stoeckel, L. E., et al. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.185 · Cited by 1,597 · see citing works
Silverman, M. G., Ference, B. A., Im, K., Wiviott, S. D., Giugliano, R. P., Grundy, S. M., Braunwald, E., & Sabatine, M. S. (2016) · JAMA · doi:10.1001/jama.2016.13985 · Cited by 1,483 · cited 1× · see citing works
“…controlled trials demonstrated a log-linear relationship between the absolute changes in plasma LDL and the risk of atherosclerotic cardiovascular diseases (ASCVDs) [14,15], which include coronary heart disease, cerebrovascular disease, peripheral artery disease, and aortic atherosclerotic disease.”
The Role of Lipids and Lipoproteins in Atherosclerosis
Gofman, J. W., Lindgren, F. T., Elliott, H. A., Mantz, W., Hewitt, J. E., Strisower, B., Herring, V. V., & Lyon, T. P. (1950) · Science · doi:10.1126/science.111.2877.166 · Cited by 921 · see citing works
Diabetes and atherosclerosis: An epidemiologic view
Pyörälà, K., Laakso, M., & Uusitupa, M. I. J. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030206 · Cited by 912 · see citing works
Ference, B. A., Yoo, W., Alesh, I., Mahajan, N., Mirowska, K. K., Mewada, A., Kahn, J., Afonso, L., Williams, K. A., & Flack, J. M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.017 · Cited by 898 · see citing works
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · see citing works
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
Yusuf, S., Bosch, J., Dagenais, G., Zhu, J., Xavier, D., Liu, L., Pais, P., López-Jaramillo, P., Leiter, L. A., Dans, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600176 · Cited by 848 · see citing works
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829 · see citing works
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · see citing works
Goldstein, J. L., & Brown, M. S. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.10.2804 · Cited by 454 · see citing works
Inflammation during the life cycle of the atherosclerotic plaque
Libby, P. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab303 · Cited by 437 · see citing works
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429 · see citing works
George Lyman Duff Memorial Lecture. Atherogenesis in diabetes.
Bierman, E. L. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.6.647 · Cited by 412 · see citing works
Giachelli, C. M., Lombardi, D. M., Johnson, R. J., Murry, C. E., & de Almeida, M. A. G. (1998) · Europe PMC (PubMed Central) · Cited by 370 · see citing works
Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P., Bézard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 313 · see citing works
ULTRACENTRIFUGAL STUDIES OF LIPOPROTEINS OF HUMAN SERUM
Gofman, J. W., Lindgren, F. T., & Elliott, H. A. (1949) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)51290-x · Cited by 291 · see citing works
Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Ceriello, A., Chiodini, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01366-8 · Cited by 263 · cited 1× · see citing works
“The GLP-1RAs were shown to have pleiotropic CV effects [41] including reduction in blood pressure (BP) [42].”
Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259 · see citing works
LOX-1: Regulation, Signaling and Its Role in Atherosclerosis
Kattoor, A. J., Goel, A., & Mehta, J. L. (2019) · Antioxidants · doi:10.3390/antiox8070218 · Cited by 257 · see citing works
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.11.008 · Cited by 232 · see citing works
Petit, J., Cercueil, J., Loffroy, R., Denimal, D., Bouillet, B., Fourmont, C., Chevallier, O., Duvillard, L., & Vergès, B. L. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2775 · Cited by 228 · see citing works
Skov, J., Dejgaard, A., Frøkiær, J., Holst, J. J., Jonassen, T., Rittig, S., & Christiansen, J. S. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3855 · Cited by 228 · see citing works
Mechanisms of plaque stabilization with statins
Libby, P., & Aikawa, M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03267-8 · Cited by 225 · see citing works
Hypertension management in patients with cardiovascular comorbidities
Lauder, L., Mahfoud, F., Azizi, M., Bhatt, D. L., Ewen, S., Kario, K., Parati, G., Rossignol, P., Schlaich, M. P., Teo, K. K., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac395 · Cited by 217 · see citing works
Husain, M., Bain, S. C., Jeppesen, O. K., Lingvay, I., Sørrig, R., Treppendahl, M. B., & Vilsbøll, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13955 · Cited by 209 · see citing works
Longo, S., Rizza, S., & Federici, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02088-x · Cited by 202 · see citing works
Self-citationLipoproteins, Coronary Heart Disease, and Atherosclerosis
Gofman, J. W., Glazier, F., Tamplin, A. R., Strisower, B., & Lalla, O. F. D. (1954) · Physiological Reviews · doi:10.1152/physrev.1954.34.3.589 · Cited by 202 · see citing works
Hurt‐Camejo, E., Camejo, G., Rosengren, B. E., López, F., Ahlström, C., Fager, G., & Bondjers, G. (1992) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology · doi:10.1161/01.atv.12.5.569 · Cited by 184 · see citing works
Sposito, A. C., Berwanger, O., de Carvalho, L. S. F., & Saraiva, J. F. K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0800-2 · Cited by 171 · see citing works
(2010) · PubMed Central · Cited by 169 · see citing works
Tashiro, Y., Sato, K., Watanabe, T., Nohtomi, K., Terasaki, M., Nagashima, M., & Hirano, T. (2014) · Peptides · doi:10.1016/j.peptides.2013.12.015 · Cited by 149 · see citing works
Ferdinand, K. C., White, W. B., Calhoun, D. A., Lonn, E., Sager, P. T., Brunelle, R. L., Jiang, H. H., Threlkeld, R. J., Robertson, K. E., & Geiger, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03062 · Cited by 146 · see citing works
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Tan, Q., Akindehin, S. E., Orsso, C. E., Waldner, R. C., DiMarchi, R. D., Müller, T. D., & Haqq, A. M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.838410 · Cited by 146 · see citing works
Lingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity · doi:10.1002/oby.23621 · Cited by 113 · cited 1× · see citing works
“In that study, which is one of the largest CV outcome trials in the field of obesity, semaglutide at a dose of 2.4 mg once weekly is being evaluated to reduce CV events in people with overweight or obesity and previous CVD but without diabetes [71].”
InfluentialA New Alzheimers Disease Interventive Strategy: GLP-1
Perry, T. R., & Greig, N. H. (2004) · Current Drug Targets · doi:10.2174/1389450043345245 · Cited by 112 · see citing works
An update on peptide-based therapies for type 2 diabetes and obesity
Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2023) · Peptides · doi:10.1016/j.peptides.2023.170939 · Cited by 111 · see citing works
GLP-1a: Going beyond Traditional Use
Laurindo, L. F., Barbalho, S. M., Guiguer, E. L., da Silva Soares de Souza, M., de Souza, G. A., Fidalgo, T. M., Araújo, A. C., de Souza Gonzaga, H. F., de Bortoli Teixeira, D., de Oliveira Silva Ullmann, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020739 · Cited by 102 · cited 1× · see citing works
“Data from human clinical trials have shown an improvement in some brain markers but have not thus far demonstrated a strong correlation to cognitive scores [75,78].”
(1983) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.3.2.178 · Cited by 101 · see citing works
GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes
Monney, M., Jornayvaz, F. R., & Gariani, K. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101470 · Cited by 99 · see citing works
Prandi, F. R., Evangelista, I., Sergi, D., Palazzuoli, A., & Romeo, F. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10200-y · Cited by 83 · see citing works
Self-citationLiraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis
Bruen, R., Curley, S., Kajani, S., Crean, D., O'Reilly, M. E., Lucitt, M. B., Godson, C., McGillicuddy, F. C., & Belton, O. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0626-3 · Cited by 81 · see citing works
Endogenous Activation of Glucagon-Like Peptide-1 Receptor Contributes to Blood Pressure Control
Martins, F. L., Bailey, M. A., & Girardi, A. C. C. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.14868 · Cited by 75 · see citing works
Luo, X.-J., Hu, Y., He, S., Ye, Q., Lv, Z.-B., Liu, J.-X., & Chen, X.-P. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.07.008 · Cited by 68 · see citing works
Hofmann, A., Brunssen, C., & Morawietz, H. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.10.002 · Cited by 68 · see citing works
Glucose variability: a new risk factor for cardiovascular disease
Belli, M., Bellia, A., Sergi, D., Barone, L., Lauro, D., & Barillà, F. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02097-w · Cited by 66 · see citing works
Self-citationEfficacy and safety of semaglutide for weight management: evidence from the STEP program
Amaro, A., Sugimoto, D. H., & Wharton, S. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2147326 · Cited by 65 · see citing works
Jantrapirom, S., Nimlamool, W., Chattipakorn, N., Chattipakorn, S. C., Temviriyanukul, P., Inthachat, W., Govitrapong, P., & Potikanond, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051725 · Cited by 63 · see citing works
Liao, C., Liang, X., Zhang, X., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0289616 · Cited by 63 · see citing works
Peradze, N., Farr, O. M., Perakakis, N., Lázaro, I., Sala‐Vila, A., & Mantzoros, C. S. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0945-7 · Cited by 61 · see citing works
Pandey, S., Mangmool, S., & Parichatikanond, W. (2023) · Pharmaceuticals · doi:10.3390/ph16060836 · Cited by 58 · see citing works
Inflammation in atherosclerotic cardiovascular disease
Shah, P. K., & Lecis, D. (2019) · F1000Research · doi:10.12688/f1000research.18901.1 · Cited by 58 · see citing works
Self-citationBruen, R., Curley, S., Kajani, S., Lynch, G. M., O'Reilly, M. E., Dillon, E., Brennan, E. P., Barry, M. C., Sheehan, S. J., McGillicuddy, F. C., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258343 · Cited by 54 · see citing works
Li, Y., Chen, L., Li, D., Xu, H. Y., Chen, J., Min, X., He, M., Wu, T., Zhong, J., Yang, H., et al. (2021) · Mediators of Inflammation · doi:10.1155/2021/5568159 · Cited by 45 · see citing works
Freeman-Anderson, N. E., Rusiñol, A. E., Linton, M. F., Hachey, D. L., Fazio, S., Sinensky, M. S., & Thewke, D. P. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500101-jlr200 · Cited by 42 · see citing works
Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
Waldrop, G. E., Zhong, J., Peters, M. C., Goud, A., Chen, Y., Davis, S. N., Mukherjee, B., & Rajagopalan, S. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.08.018 · Cited by 40 · see citing works
Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
Lutz, T. A., & Osto, E. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000293 · Cited by 39 · see citing works
Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease
Andreadi, A., Muscoli, S., Tajmir, R., Meloni, M., Muscoli, C., Ilari, S., Mollace, V., Della‐Morte, D., Bellia, A., Daniele, N. D., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021646 · Cited by 37 · see citing works
Self-citationPrandi, F. R., Lecis, D., Illuminato, F., Milite, M., Celotto, R., Lerakis, S., Romeo, F., & Barillà, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094589 · Cited by 35 · see citing works
Self-citationYaribeygi, H., Farrokhi, F. R., Abdalla, M. A., Sathyapalan, T., Banach, M., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/6518221 · Cited by 31 · see citing works
Owens, D. R., Monnier, L., & Markolf Hanefeld, E. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12998 · Cited by 29 · see citing works
Bone markers and cardiovascular risk in type 2 diabetes patients
Zwakenberg, S. R., van der Schouw, Y. T., Schalkwijk, C. G., Spijkerman, A. M. W., & Beulens, J. W. J. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0691-2 · Cited by 29 · see citing works
Kharbanda, R. K., Wallace, S. M. L., Walton, B., Donald, A. E., Cross, J., & Deanfield, J. E. (2005) · Circulation · doi:10.1161/01.cir.0000155236.25081.9b · Cited by 22 · see citing works
Gumieniczek, A., & Berecka-Rycerz, A. (2023) · Biomedicines · doi:10.3390/biomedicines11082127 · Cited by 15 · see citing works
Role of acyl-coenzyme A: cholesterol transferase 1 (ACAT1) in retinal neovascularization
Zaidi, S. A. H., Lemtalsi, T., Xu, Z., Santana, I. N., Sandow, P. V., Labazi, L., Caldwell, R. W., Caldwell, R. B., & Rojas, M. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02700-5 · Cited by 14 · see citing works
Le, Y., Zheng, Z., Xue, J., Cheng, M., Guan, M., & Xue, Y. (2016) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320316677918 · Cited by 12 · see citing works
Incretins: B eyond type 2 diabetes
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 12 · see citing works
Genetics and molecular biology: macrophage ACAT depletion – mechanisms of atherogenesis
Akopian, D., & Medh, J. D. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000203192.45649.ba · Cited by 9 · see citing works
Flagged first, then by citations
3 of the 83 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H., Peters, T. M., & Eisenberg, M. J. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.01.021 · Cited by 241 · see citing works
The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy
Abbass, N. J., Nahlawi, R., Shaia, J. K., Allan, K. C., Kaelber, D. C., Talcott, K. E., & Singh, R. P. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.02.025 · Cited by 78 · see citing works
Innovations and challenges in collagen and gelatin production through precision fermentation
Campos, S. D. M., Costa, G. D. S., Karp, S. G., Thomaz‐Soccol, V., & Soccol, C. R. (2025) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-025-04276-z · Cited by 29 · see citing works
Role of MASLD in CVD: A review of emerging treatment options
Mollace, R., Longo, S., Nardin, M., Tavernese, A., Musolino, V., Cardamone, A., & Federici, M. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111891 · Cited by 23 · see citing works
Self-citationCozza, A., Chinigò, C., Filicetti, E., Greco, G. I., Lappano, R., Marinaro, C., Muglia, L., Soraci, L., Corsonello, A., Lattanzio, F., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102834 · Cited by 20 · see citing works
Incretin-Based Therapies Through the Decades: Molecular Innovations and Clinical Impact
Lee, A. A., Khotina, V. A., Kashirskikh, D. A., Voronko, O. E., Gasanov, V. A. O., & Vasiliev, A. V. (2025) · Medical Sciences · doi:10.3390/medsci13040269 · Cited by 16 · see citing works
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
Morissette, A., & Mulvihill, E. E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.012 · Cited by 11 · see citing works
Beyond Blood Sugar: A Scoping Review of GLP-1 Receptor Agonists in Cardiovascular Care
Gupta, N., Zayyad, Z. A., Bhattaram, R., Tiu, D. R., Dau, J., Guburxani, V., Kalzuna, S. D., & Shroff, A. R. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00426-4 · Cited by 10 · see citing works
Longo, S., Rinaldi, T. G., Fernández‐Real, J. M., & Federici, M. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01623-8 · Cited by 6 · see citing works
Self-citationLu, X., & Yang, L. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1763185 · Cited by 5 · see citing works
Ahmed, M., Hashmi, T. M., Shahzad, M., Zia, R., Ashraf, H., Ahmed, R., Rashid, M. O., Greene, S. J., Mentz, R. J., Fudim, M., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag079 · Cited by 4 · see citing works
Schulz, M. E., Akerstrom, V. L., Dayan, J. H., & Castorena‐Gonzalez, J. A. (2026) · Microcirculation · doi:10.1111/micc.70070 · Cited by 4 · see citing works
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 2 · see citing works
GLP-1R Agonism Directly Improves the Pumping Capacity of Murine Collecting Lymphatic VesselsPreprint
Schulz, M. E., Akerstrom, V. L., Dayan, J. H., & Castorena‐Gonzalez, J. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.26.696603 · Cited by 2 · see citing works
The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review
Luca, S. A., Bungau, R. M., Lazăr, S., Herascu, A., Gaiţă, L., Avram, V. F., & Timar, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196877 · Cited by 1 · see citing works
Zawadzki, M., & Karczewska‐Kupczewska, M. (2026) · Cardiovascular Therapeutics · doi:10.1155/cdr/8388511 · Cited by 1 · see citing works
Kennedy, S., Thomas, J., Darcy, S., Odia, I., Kamdar, D., Pereira, L., Scarola, D., Miles, B., Frank, D. K., Taneja, C., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1834606 · Cited by 1 · see citing works
Mihalache, L., & Graur, L. I. (2025) · Springer eBooks · doi:10.1007/978-3-032-11445-7_8
Arun, A. J., Darji, B., Maksymiuk, V., Baig, M., & Frishman, W. H. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001240
Rodriguez, M. E., Lavell, J., & Foreman, R. M. (2026) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000430
Zibaoui, R. E., McDonald, T. J. W., Henry-Barron, B. J., Vizthum, D., & Cervenka, M. C. (2026) · Epilepsy Research · doi:10.1016/j.eplepsyres.2026.107896
Strugała, N., Kostrzewski, M., Noworolska, M., Wojtaszkiewicz, D., Skrzeczyna, J., Sapała, E., Bednarska, K., Zurek, J., Wiśniewska, M., Bulenda, M., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6003
Yuan, Y., Chen, C., Li, X., Guo, J., Liu, Q., Lin, Y., Sun, L., & Fan, G. (2026) · Drugs · doi:10.1007/s40265-026-02380-4
- Authors
- Lecis, D., Prandi, F. R., Barone, L., Belli, M., Sergi, D., Longo, S., Muscoli, S., Romeo, F., Federici, M., Lerakis, S., & Barillà, F.
- Affiliations
- University of Rome Tor Vergata (IT)
- Saint Camillus International University of Health and Medical Sciences (IT)
- Mount Sinai Hospital (US)
- Corresponding author
- Lecis, Dalgisio
- ORCID
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2023-11-23
- Volume
- 13
- Issue
- 12
- Pages
- 1695
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC10741698
- OpenAlex
- W4388938779
- Cited by
- 23
- References
- 83
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 2
- FWCI
- 0.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- GLP-1 receptor agonists, atherosclerosis, plaque stabilization, weight loss, type 2 diabetes, atheroprotection, immunomodulation, statins, cardiovascular risk
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
